What we do OneSource Specialty Pharma Ltd is an Indian specialty pharmaceutical Contract Development and Manufacturing Organization focused on biologics, injectables, and oral drug-device combinations. |
Founded in 2,007 |
Market share India's leading specialty pharma CDMO with a growing global footprint serving top generic and innovator pharma companies. |
Problem solved Enables biotech and pharma companies to develop and manufacture complex biological and injectable drug products at scale. |
Top clients or who we serve Serves global pharmaceutical generics, innovator pharma, biotechs, and R&D houses (B2B). |
Key management Neeraj Sharma, Managing Director; Arun Kumar, Chairperson; senior leaders with extensive pharma and biotech experience. |
Our journey and innovations Incorporated in 2007; became OneSource in 2024 after strategic mergers; expanded biologics CDMO and drug-device combo capabilities. |
Where we operate India, USA, Ireland, and other global markets. |
Top products or what we offer Contract development and manufacturing of biologics, injectables, drug-device combinations, soft gelatin capsules. |
Top brands No specific brands; highly regarded for biologics CDMO services and multi-modal injectable manufacturing. |
Raw materials needed Biological substances, active pharmaceutical ingredients, solvents, polymers for drug-device combos. |
Raw materials supplier Supplied by global pharmaceutical ingredient providers under strict quality standards. |
Recurring vs cyclical contribution Revenue primarily from recurring CDMO contracts with stable client engagements. |
Our industry position One of India’s largest specialty pharma CDMOs with 5 global facilities and strong compliance track record. |
Financial highlights FY25 revenue ₹1,444.85 Cr; EBITDA positive at ₹4,665 million; first profitable year with ₹936 million PAT (adjusted). |
Geographical revenue split Revenue split FY25: India ₹194 Cr, USA ₹506 Cr, Ireland ₹175 Cr, Rest of World ₹569 Cr. |
Order book Strong order book driven by new customer contracts across biologics, injectables, and drug-device combinations. |
Whats driving growth Rising biologics demand, expanding injectables capacity, regulatory tailwinds, and strategic acquisitions. |
Our future plans Accelerate capacity expansions, invest $100m capex by FY28, integrate acquisitions, target $500m revenue. |
Our green promise Committed to sustainability with renewable energy adoption and global ESG framework alignment. |
Our people and values 1,296 employees fostering innovation, compliance, and inclusion with a focus on pharma excellence. |
Key challenges ahead Managing integration risks, regulatory compliance, competitive CDMO landscape, and capital expenditure execution. |
Interesting facts First pure-play specialty pharma CDMO in India post-2024 demerger; recent $95 million funding led by marquee investors. |
Risks and strategy Risks include regulatory shifts and market competition; mitigated by diversified capabilities and strong governance. |
